Avalo Therapeutics Has Dosed The First Patient In The Phase 2 LOTUS trial Of AVTX-009 In Hidradenitis Suppurativa, Topline Data From The Global Study In Approximately 180 Adults Is Expected In 2026
Portfolio Pulse from Benzinga Newsdesk
Avalo Therapeutics has initiated the Phase 2 LOTUS trial for AVTX-009, targeting Hidradenitis Suppurativa. The trial will involve approximately 180 adults, with topline data expected in 2026.
October 08, 2024 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avalo Therapeutics has dosed the first patient in its Phase 2 LOTUS trial for AVTX-009, targeting Hidradenitis Suppurativa. This marks a significant step in their clinical development, with results expected in 2026.
The initiation of a Phase 2 trial is a positive development for Avalo Therapeutics, indicating progress in their drug development pipeline. This could lead to increased investor interest and potential stock price appreciation, although the long timeline until 2026 for topline data may temper immediate impacts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100